Literature DB >> 27558391

[Invasive treatment of hypertension : Update 2016].

J Menne1, R Wachter2.   

Abstract

Invasive treatment methods-more specifically renal denervation and baroreceptor activator therapy-have been used for the treatment of therapy-resistant hypertension for several years now. In particular, renal denervation has aroused great interest because it was easy to perform and the first studies provided very promising results. Meanwhile, however, three randomized, blinded studies have been published, and none showed a significant benefit of renal denervation compared to a sham procedure. In addition, in several studies it was demonstrated that intensification of drug therapy, particularly with spironolactone, is at least comparable. Carotid sinus node baroreceptor activator therapy tends to be superior to renal denervation, but the probe currently used is not optimal. The first results by inserting an arteriovenous shunt between the iliac artery and vein are promising, but lack long-term safety data. Currently, all invasive treatment procedures should be performed within the framework of studies or accurate register surveys.

Entities:  

Keywords:  Arteriovenous shunt; Baroreceptors; Denervation, renal; Drug resistance, hypertension; Spironolactone

Mesh:

Substances:

Year:  2016        PMID: 27558391     DOI: 10.1007/s00108-016-0116-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  23 in total

1.  Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension.

Authors:  Fadl Elmula M Fadl Elmula; Yu Jin; Wen-Yi Yang; Lutgarde Thijs; Yi-Chao Lu; Anne C Larstorp; Alexandre Persu; Marc Sapoval; Ján Rosa; Petr Widimský; Lotte Jacobs; Jean Renkin; Ondřej Petrák; Gilles Chatellier; Kazuyuki Shimada; Jiři Widimský; Kazuomi Kario; Michel Azizi; Sverre E Kjeldsen; Jan A Staessen
Journal:  Blood Press       Date:  2015-07-17       Impact factor: 2.835

2.  Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity.

Authors:  Atul Pathak; Leslie Coleman; Austin Roth; James Stanley; Lynn Bailey; Peter Markham; Sebastian Ewen; Charlotte Morel; Fabien Despas; Benjamin Honton; Jean Michel Senard; Jean Fajadet; Felix Mahfoud
Journal:  EuroIntervention       Date:  2015-08       Impact factor: 6.534

3.  Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension.

Authors:  Steffen Desch; Thomas Okon; Diana Heinemann; Konrad Kulle; Karoline Röhnert; Melanie Sonnabend; Martin Petzold; Ulrike Müller; Gerhard Schuler; Ingo Eitel; Holger Thiele; Philipp Lurz
Journal:  Hypertension       Date:  2015-03-30       Impact factor: 10.190

4.  Baroreflex activation therapy in patients with prior renal denervation.

Authors:  Manuel Wallbach; Marcel Halbach; Hannes Reuter; Jens Passauer; Stephan Lüders; Enrico Böhning; Dieter Zenker; Gerhard A Müller; Rolf Wachter; Michael J Koziolek
Journal:  J Hypertens       Date:  2016-08       Impact factor: 4.844

5.  Externally Delivered Focused Ultrasound for Renal Denervation.

Authors:  Petr Neuzil; John Ormiston; Todd J Brinton; Zdenek Starek; Murray Esler; Omar Dawood; Thomas L Anderson; Michael Gertner; Rob Whitbourne; Roland E Schmieder
Journal:  JACC Cardiovasc Interv       Date:  2016-06-20       Impact factor: 11.195

6.  Endovascular ultrasound for renal sympathetic denervation in patients with therapy-resistant hypertension not responding to radiofrequency renal sympathetic denervation.

Authors:  Thomas Stiermaier; Thomas Okon; Karl Fengler; Ulrike Mueller; Robert Hoellriegel; Gerhard Schuler; Steffen Desch; Philipp Lurz
Journal:  EuroIntervention       Date:  2016-06-12       Impact factor: 6.534

7.  Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial.

Authors:  Melvin D Lobo; Paul A Sobotka; Alice Stanton; John R Cockcroft; Neil Sulke; Eamon Dolan; Markus van der Giet; Joachim Hoyer; Stephen S Furniss; John P Foran; Adam Witkowski; Andrzej Januszewicz; Danny Schoors; Konstantinos Tsioufis; Benno J Rensing; Benjamin Scott; G André Ng; Christian Ott; Roland E Schmieder
Journal:  Lancet       Date:  2015-01-23       Impact factor: 79.321

8.  Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study.

Authors:  Ján Rosa; Petr Widimský; Petr Waldauf; Lukáš Lambert; Tomáš Zelinka; Miloš Táborský; Marian Branny; Petr Toušek; Ondřej Petrák; Karol Čurila; František Bednář; Robert Holaj; Branislav Štrauch; Jan Václavík; Igor Nykl; Zuzana Krátká; Eva Kociánová; Otakar Jiravský; Gabriela Rappová; Tomáš Indra; Jiří Widimský
Journal:  Hypertension       Date:  2015-12-22       Impact factor: 10.190

9.  Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.

Authors:  Anna Oliveras; Pedro Armario; Albert Clarà; Laia Sans-Atxer; Susana Vázquez; Julio Pascual; Alejandro De la Sierra
Journal:  J Hypertens       Date:  2016-09       Impact factor: 4.844

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.